Medicus Pharma CEO Highlights FDA Milestones and Clinical Progress for 2026

Jul 2, 2026

Medicus Pharma (NASDAQ: MDCX) CEO Dr. Raza Bokhari discusses the company’s major achievements during the first half of 2026, including positive Phase 2 results for SkinJect, preparations for an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), and continued advancement of the company’s clinical pipeline. He also provides updates on the development of Teverelix for advanced prostate cancer and endometriosis.

Dr. Bokhari also outlines several important regulatory catalysts expected in the coming months, including FDA decisions on Orphan Drug Designation, Rare Pediatric Disease Designation, and the company’s proposed pivotal study for patients with Gorlin syndrome. These milestones could play a significant role in advancing Medicus Pharma’s commercialization strategy and long-term shareholder value.

#MedicusPharma
#MDCX
#SkinJect
#Teverelix
#Biotech
#ClinicalTrials
#FDA
#OrphanDrug
#RareDisease
#BasalCellCarcinoma
#ProstateCancer
#Endometriosis
#NASDAQ
#JaneKing
#NewsOut